Twelve-year cumulative incidence of airflow obstruction among Japanese males

Internal Medicine

Volumn 50, Issue 15, 2011, Pages 1537-1544

  Omori, Hisamitsu ^a   Nagano, Megumi ^b   Funakoshi, Yayoi ^a   Onoue, Ayumi ^a   Mihara, Shuichi ^c   Marubayashi, Tohru ^c   Kohrogi, Hirotsugu ^a   Aizawa, Hisamichi ^d   Katoh, Takahiko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO HEALTH SCIENCE UNIVERSITY   (Japan)

^c JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Airflow obstruction; COPD; Epidemiology; Health check up; Lower limit of normal; Lung function

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; SMOKING; SMOKING CESSATION; SPIROMETRY;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FORCED EXPIRATORY VOLUME; HUMANS; INCIDENCE; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SPIROMETRY; VITAL CAPACITY;

EID: 79961195193     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4412     Document Type: Article

References (32)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2009. Available at: www.goldcopd.com.Last accessed 30 March 2010.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765-773, 2007.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504, 1997.
4. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 22: 268-273, 2003.
5. Celli BR, Mac-Nee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932-946, 2004.
6. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 68: 4-19, 2001.
7. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systemic review and metaanalysis. Eur Respir J 28: 523-532, 2006.
8. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 9: 458-465, 2004.
9. Menezes AM, Perez-Padilla R, Jardim JR, et al; PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 366: 1875-1881, 2005.
10. Buist AS, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 370: 741-750, 2007.
11. Rennard S, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 367: 1216-1219, 2006.
12. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 61: 935-939, 2006.
13. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Mørkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 20: 1117-1122, 2002.
14. Köhler D, Fischer J, Raschke F, Schönhofer B. Usefulness of GOLD classification of COPD severity. Thorax 58: 825, 2003.
15. Pellegrino R, Brusasco V, Viegi G, et al. Definition of COPD: based on evidence or opinion? Eur Respir J 31: 681-682, 2008.
16. Vollmer WM, Gislason P, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 34: 588-597, 2009.
17. Osaka D, Shibata Y, Abe S, et al. Relationship between habit of cigarette smoking and airflow limitation in healthy Japanese individuals: The Takahata Study. Intern Med 49: 1489-1499, 2010.
18. Pelkonen M, Notkola IL, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality; a follow-up in middle-aged rural men. Chest 130: 1129-1137, 2006.
19. Kohansal R, Martinez-Camblor P, Agust A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited. An analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 180: 3-10, 2009.
20. Lindberg A, Eriksson B, Larsson LG, Rönmark E, Sandström T, Lundbäck B. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 129: 879-885, 2006.
21. Lindberg A, Jonsson AC, Rönmark E, Lundgren R, Larsson LG, Lundbäck B. Ten-year cumulative incidence of COPD and risk factors for incident disease in a symptomatic cohort. Chest 127: 1544-1552, 2005.
22. Omori H, Nonami Y, Morimoto Y. Effect of smoking on FEV1 decline in a cross-sectional and longitudinal study of a large cohort of Japanese males. Respirology 10: 464-469, 2005.
23. Omori H, Nakashima R, Otsuka N, et al. Emphysema detected by lung cancer screening with low-dose spiral CT: prevalence, and correlation with smoking habits and pulmonary function in Japanese male subjects. Respirology 11: 205-210, 2006.
24. Omori H, Tsuji M, Sata K, et al. Correlation of C-reactive protein with disease severity in CT diagnosed emphysema. Respirology 14: 551-558, 2009.
25. Brusasco V, Crapo R, Viegi G; American Thoracic Society, European Respiratory Society. Coming together: the ATS/ERS consen-sus on clinical pulmonary function testing. Eur Respir J 26: 1-2, 2005.
26. Japanese Respiratory Society. Available at http://www.jrs.or.jp/quicklink/glsm/guideline/nopass_pdf/spirogram.pdf.
27. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 374: 733-743, 2009.
28. Viegi G, Pedreschi M, Pistelli F, et al. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 117: 339S-345S, 2000.
29. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 63: 1046-1051, 2008.
30. Probst-Hensch NM, Curjuric I, Bridevaux PO, et al. Longitudinal change of pre-bronchodilator spirometric obstruction and health outcomes: results from the SAPALDIA cohort. Thorax 65: 150-156, 2010.
31. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 166: 329-332, 2002.
32. Martinez FJ, Curtis JL, Sciurba F, et al; National Emphysema Treatment Trial Research Group. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med 176: 243-252, 2007.